ClinicalTrials.gg
CompletedNCT02861014Updated Jan 27, 2022Results posted

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

A Phase 3 interventional study of Ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, sponsored by Hoffmann-La Roche. Completed at 163 sites in 17 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2022-01-27.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
681
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting — 2 open to participants now, 5 under way, 3 of them phase 3. ocrelizumab · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
3rd of 10
681 · median 404
Started
2016
with 1 other
Phase 3
6 of 10
1 open now
Registered
3rd of 10
by date
Lead sponsor
4 of 10
Hoffmann-La Roche

Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, this one is the 3rd largest by enrollment, is one of 2 that started in 2016, is one of 6 in phase 3, and was the 3rd registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

2 of the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ocrelizumab

ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, or all of them as a file.
02

Study summary

The purpose of this prospective, multicenter, open-label, efficacy, and safety study is to assess the efficacy and safety of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS) who have had a suboptimal response to an adequate course of a Disease-Modifying Treatment (DMT). The study will consist of a Screening period (up to 4 weeks), an Open-label treatment period (96 weeks; with last dose administered at Week 72), and a Follow-up period of at least 2 years.

03

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a definite diagnosis of RRMS, confirmed as per the revised McDonald 2010 criteria
  • Have a length of disease duration, from first symptom, of less than (\<) 10 years
  • Have received no more than two prior DMTs, and the discontinuation of the most recent DMT was due to lack of efficacy
  • Suboptimal disease control while on a DMT
  • Expanded Disability Status Scale (EDSS) of 0.0 to 4.0, inclusive, at Screening
  • For women of : agreement to use an acceptable method during the treatment period and for at least 6 months after the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • Secondary progressive multiple sclerosis (SPMS) or history of primary progressive or progressive relapsing multiple sclerosis (MS)
  • Inability to complete an Magnetic Resonance Imaging (MRI) procedure
  • Known presence of other neurological disorders
  • Any concomitant disease that may require chronic treatment with systemic or during the course of the study
  • History or currently active primary or secondary immunodeficiency
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
  • History of opportunistic infections
  • History or known presence of recurrent or chronic infection
  • History of
  • Congestive heart failure
  • Known active bacterial, viral, fungal, mycobacterial infection or other infection, excluding fungal infection of nail beds
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
681 participants (actual)

Study arms

  • Experimental
    Ocrelizumab

    Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.

    Biological: Ocrelizumab

Interventions

  • BiologicalOcrelizumab

    Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.

    Also known as: RO4964913

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With No Evidence of Disease Activity (NEDA) as Per Protocol Defined Events During a 96-Week Period

    A protocol-defined event of disease activity was defined by the occurrence of at least one of the following while on treatment with ocrelizumab: * A protocol-defined relapse (PDR) * 24-week CDP based on increase in EDSS while on treatment with ocrelizumab * A T1 Gd-enhanced lesion after Week 8 * A new and/or enlarging T2 hyperintense lesion on MRI after Week 8 compared to the Week 8 MRI scan

    Time frame: Week 96

Secondary outcomes

  1. Percentage of Participants Free From a Protocol-Defined Event of Disease Activity During 24 Weeks Period

    A protocol-defined event of disease activity was defined by the occurrence of at least one of the following while on treatment with ocrelizumab: * A protocol-defined relapse (PDR) * 24-week CDP based on increase in EDSS while on treatment with ocrelizumab * A T1 Gd-enhanced lesion after Week 8 * A new and/or enlarging T2 hyperintense lesion on MRI after Week 8 compared to the Week 8 MRI scan

    Time frame: Baseline up to 24 weeks

  2. Percentage of Participants Free From a Protocol-Defined Event of Disease Activity During 48 Weeks Period

    A protocol-defined event of disease activity was defined by the occurrence of at least one of the following while on treatment with ocrelizumab: * A protocol-defined relapse (PDR) * 24-week CDP based on increase in EDSS while on treatment with ocrelizumab * A T1 Gd-enhanced lesion after Week 8 * A new and/or enlarging T2 hyperintense lesion on MRI after Week 8 compared to the Week 8 MRI scan

    Time frame: Baseline up to 48 weeks

  3. Time to First Protocol-Defined Event of Disease Activity

    The definition of a protocol-defined event of disease activity is the occurrence of at least one of the following while on treatment with ocrelizumab: * A protocol-defined relapse defined as: Symptoms must persist for \>24 hours and should not be attributable to confounding clinical factors; Symptoms should be preceded by neurological stability for at least 30 days; Symptoms should be accompanied by new objective neurological worsening determined with a timely EDSS/ Functional Systems Score (FSS) assessment * 24 weeks confirmed disability progression based on increases in EDSS while on treatment with ocrelizumab * A T1 Gd-enhanced lesion after Week 8 * A new and/or enlarging T2 hyperintense lesion on MRI after Week 8 compared to the Week 8 MRI scan.

    Time frame: Baseline up to 96 Weeks

  4. Change From Baseline to Week 96 in Expanded Disability Status Scale (EDSS)

    The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments.

    Time frame: Baseline, Weeks: 24, 48, 72, 96

  5. Absolute Change From Baseline in EDSS Category at Week 96

    The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments.

    Time frame: Up to Week 96

  6. Percentage of Participants With a Baseline EDSS Score ≥2 With CDI at Week 96

    The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments.

    Time frame: Week 96

  7. Annualized Protocol-defined Relapse Rate at Week 96

    Time frame: Week 96

  8. Time to Onset of 24-week Confirmed Disability Progression

    Time frame: Baseline up to 96 Weeks

  9. Time to Onset of First Protocol-Defined Relapse

    A protocol-defined multiple sclerosis (MS) relapse is an occurrence of new or worsening neurological symptoms attributable to MS that meets the following criteria: * Symptoms must persist for \>24 hours and should not be attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications) * Symptoms should be preceded by neurological stability for at least 30 days * Symptoms should be accompanied by new objective neurological worsening determined with a timely EDSS/ Functional Systems Score (FSS) assessment, consistent with an increase of at least: * ≥ 0.5 points on EDSS scale * or ≥ 2 points on one of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual * or ≥ 1 point on two or more of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual

    Time frame: Baseline up to 96 Weeks

  10. Time to Onset of First New and/or Enlarging T2 Lesion

    Time frame: Baseline up to 96 Weeks

  11. Mean Number of T1 Gd-enhancing Lesions Per MRI Scan at Weeks 24, 48 and 96

    Mean number of T1 Gd-enhancing lesions per MRI scan: Total number of T1 Gd-enhanced lesions divided by the total number of interpretable MRI scans

    Time frame: Weeks: 24, 48, 96

  12. Change From Baseline to Week 96 in Total T2 Lesion Volume Detected by Brain MRI From

    Time frame: Baseline, Week 96

  13. Percentage Change From Baseline to Week 96 in Total T2 Lesion Volume Detected by Brain MRI

    Time frame: Baseline, Week 96

  14. Volume of New and/or Enlarging T2 Hyperintense Lesions Volume of Lesions Per MRI Scan at Weeks 24, 48, 96

    The number of new and/or enlarging T2 lesions at week 24, 48 and 96 is calculated as the sum of the individual number of new and/or enlarging lesions at each visit. Data from other unscheduled assessments is included in this summary or analysis.

    Time frame: Weeks 24, 48, 96

  15. Mean Number of New and/or Enlarging T2 Hyperintense Lesions Per MRI Scan

    Mean number of new and/or enlarging T2 hyperintense lesions per MRI scan: Total number of new and/or enlarging T2 hyperintense lesions divided by the total number of interpretable MRI scans

    Time frame: Weeks 24, 48, 96

  16. Change From Baseline at Week 48 and 96 in T1 Hypointense Lesion Volume

    Time frame: Weeks 48, 96

  17. Percentage Change From Baseline at Week 48 and 96 in T1 Hypointense Lesion Volume

    Time frame: Weeks 48, 96

  18. Adjusted Mean Change From Baseline at Week 48 and 96 in T1 Hypointense Lesion Volume

    Time frame: Weeks 48, 96

  19. Adjusted Mean Percentage Change From Baseline in Brain Volume

    Time frame: Weeks 24, 48, 96

  20. Adjusted Mean Percentage Change From Baseline in Cortical Grey Matter Volume

    Time frame: Weeks 48, 96

  21. Adjusted Mean Percentage Change From Baseline in White Matter Volume

    Time frame: Weeks 48, 96

  22. Mean Change From Baseline in Cognitive Performance (Processing Speed/Working Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Symbol Digit Modalities Test (SDMT) Score

    Brief International Cognitive Assessment for MS (BICAMS) is assessing cognitive processing speed and verbal and visual memory. Symbol Digits Modalities Test (SDMT) is assessing processing speed/working memory. The SDMT presents a series of nine symbols, each paired with a single digit in a key at the top of a standard sheet of paper. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 sec. There is a single outcome measure - the number correct over the 90 sec time span. The higher the results, the better processing speed/working memory.

    Time frame: Baseline, Weeks: 48, 96

  23. Change From Baseline in Cognitive Performance (Visuospatial Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Brief Visuospatial Memory Test-Revised (BVMT-R) Score

    Brief International Cognitive Assessment for MS (BICAMS) is assessing cognitive processing speed and verbal and visual memory. Brief Visuospatial Memory Test-Revised (BVMT-R) is assessing visuospatial memory. In this test, six abstract designs are presented for 10 sec. The display is removed from view and patients render the stimuli via pencil on paper manual responses. Each design receives from 0 to 2 points representing accuracy and location. There are three learning trials, and the outcome measure is the total number of points earned over the three learning trials, thus the scale range is 0-36. The higher the result, the better visual/spatial memory.

    Time frame: Baseline, Weeks 48, 96

  24. Percentage Change From Baseline in Cognitive Performance (Processing Speed/Working Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Symbol Digit Modalities Test (SDMT) Score

    Brief International Cognitive Assessment for MS (BICAMS) is assessing cognitive processing speed and verbal and visual memory. Symbol Digits Modalities Test (SDMT) is assessing processing speed/working memory. The SDMT presents a series of nine symbols, each paired with a single digit in a key at the top of a standard sheet of paper. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 sec. There is a single outcome measure - the number correct over the 90 sec time span.

    Time frame: Baseline, Weeks 48, 96

  25. Percentage Change From Baseline in Cognitive Performance (Visuospatial Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Brief Visuospatial Memory Test-Revised (BVMT-R) Score

    Brief International Cognitive Assessment for MS (BICAMS) is assessing cognitive processing speed and verbal and visual memory. Brief Visuospatial Memory Test-Revised (BVMT-R) is assessing visuospatial memory. In this test, six abstract designs are presented for 10 sec. The display is removed from view and patients render the stimuli via pencil on paper manual responses. Each design receives from 0 to 2 points representing accuracy and location. There are three learning trials, and the outcome measure is the total number of points earned over the three learning trials, thus the scale range is 0-36. The higher the result, the better visual/spatial memory.

    Time frame: Baseline, Weeks: 48, 96

  26. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Baseline up to to 96 weeks after the end of the Treatment Period

07

Results

Posted Feb 3, 2021

Participant flow

One additional participant was initially enrolled in error and the information provided is based on the ITT population.

Primary Analysis
Participant flow — Primary Analysis
MilestoneOcrelizumab
Started680
Completed641
Not completed39
Withdrew: Adverse event7
Withdrew: Death1
Withdrew: Lack of efficacy3
Withdrew: Physician decision2
Withdrew: Pregnancy4
Withdrew: Protocol violation2
Withdrew: Study terminated by sponsor3
Withdrew: Withdrawal by subject14
Withdrew: Commercial ocrelizumab3
Safety Follow-up
Participant flow — Safety Follow-up
MilestoneOcrelizumab
Started64
Completed14
Not completed50
Withdrew: Adverse event1
Withdrew: Pregnancy1
Withdrew: Withdrawal by subject9
Withdrew: Study terminated by sponsor1
Withdrew: Physician decision1
Withdrew: Roll-over to a long term extension study1
Withdrew: Commercial ocrelizumab36

Outcome measures

PrimaryPercentage of Participants With No Evidence of Disease Activity (NEDA) as Per Protocol Defined Events During a 96-Week Period

A protocol-defined event of disease activity was defined by the occurrence of at least one of the following while on treatment with ocrelizumab: * A protocol-defined relapse (PDR) * 24-week CDP based on increase in EDSS while on treatment with ocrelizumab * A T1 Gd-enhanced lesion after Week 8 * A new and/or enlarging T2 hyperintense lesion on MRI after Week 8 compared to the Week 8 MRI scan

Time frame:
Week 96
Reported as:
Number · Percentage of Participants
Percentage of Participants With No Evidence of Disease Activity (NEDA) as Per Protocol Defined Events During a 96-Week Period
Percentage of ParticipantsOcrelizumab
Percentage of Participants With No Evidence of Disease Activity (NEDA) as Per Protocol Defined Events During a 96-Week Period74.8 (71.3 to 78.0)
SecondaryPercentage of Participants Free From a Protocol-Defined Event of Disease Activity During 24 Weeks Period

A protocol-defined event of disease activity was defined by the occurrence of at least one of the following while on treatment with ocrelizumab: * A protocol-defined relapse (PDR) * 24-week CDP based on increase in EDSS while on treatment with ocrelizumab * A T1 Gd-enhanced lesion after Week 8 * A new and/or enlarging T2 hyperintense lesion on MRI after Week 8 compared to the Week 8 MRI scan

Time frame:
Baseline up to 24 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Free From a Protocol-Defined Event of Disease Activity During 24 Weeks Period
Percentage of ParticipantsOcrelizumab
Percentage of Participants Free From a Protocol-Defined Event of Disease Activity During 24 Weeks Period87.1 (84.3 to 89.5)
SecondaryPercentage of Participants Free From a Protocol-Defined Event of Disease Activity During 48 Weeks Period

A protocol-defined event of disease activity was defined by the occurrence of at least one of the following while on treatment with ocrelizumab: * A protocol-defined relapse (PDR) * 24-week CDP based on increase in EDSS while on treatment with ocrelizumab * A T1 Gd-enhanced lesion after Week 8 * A new and/or enlarging T2 hyperintense lesion on MRI after Week 8 compared to the Week 8 MRI scan

Time frame:
Baseline up to 48 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Free From a Protocol-Defined Event of Disease Activity During 48 Weeks Period
Percentage of ParticipantsOcrelizumab
Percentage of Participants Free From a Protocol-Defined Event of Disease Activity During 48 Weeks Period82.6 (79.5 to 85.4)
SecondaryTime to First Protocol-Defined Event of Disease Activity

The definition of a protocol-defined event of disease activity is the occurrence of at least one of the following while on treatment with ocrelizumab: * A protocol-defined relapse defined as: Symptoms must persist for \>24 hours and should not be attributable to confounding clinical factors; Symptoms should be preceded by neurological stability for at least 30 days; Symptoms should be accompanied by new objective neurological worsening determined with a timely EDSS/ Functional Systems Score (FSS) assessment * 24 weeks confirmed disability progression based on increases in EDSS while on treatment with ocrelizumab * A T1 Gd-enhanced lesion after Week 8 * A new and/or enlarging T2 hyperintense lesion on MRI after Week 8 compared to the Week 8 MRI scan.

Time frame:
Baseline up to 96 Weeks
Reported as:
Median · Weeks
Time to First Protocol-Defined Event of Disease Activity
WeeksOcrelizumab
Time to First Protocol-Defined Event of Disease ActivityNA (NA to NA)
SecondaryChange From Baseline to Week 96 in Expanded Disability Status Scale (EDSS)

The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments.

Time frame:
Baseline, Weeks: 24, 48, 72, 96
Reported as:
Mean · Points on scale
Change From Baseline to Week 96 in Expanded Disability Status Scale (EDSS)
Points on scaleOcrelizumab
Baseline2.09 ± 1.06
Week 24-0.02 ± 0.64
Week 480.01 ± 0.82
Week 72-0.03 ± 0.85
Week 96-0.01 ± 0.85
SecondaryAbsolute Change From Baseline in EDSS Category at Week 96

The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments.

Time frame:
Up to Week 96
Reported as:
Number · Percentage of Participants
Absolute Change From Baseline in EDSS Category at Week 96
Percentage of ParticipantsOcrelizumab
Worsened (>0.5)13.4
Stable (Change <= 0.5 and >= -0.5)72.2
Improved (<-0.5)14.4
SecondaryPercentage of Participants With a Baseline EDSS Score ≥2 With CDI at Week 96

The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments.

Time frame:
Week 96
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Baseline EDSS Score ≥2 With CDI at Week 96
Percentage of ParticipantsOcrelizumab
Percentage of Participants With a Baseline EDSS Score ≥2 With CDI at Week 9617.3
SecondaryAnnualized Protocol-defined Relapse Rate at Week 96
Time frame:
Week 96
Reported as:
Number · Relapses per participant per year
Annualized Protocol-defined Relapse Rate at Week 96
Relapses per participant per yearOcrelizumab
Annualized Protocol-defined Relapse Rate at Week 960.030 (0.023 to 0.038)
SecondaryTime to Onset of 24-week Confirmed Disability Progression
Time frame:
Baseline up to 96 Weeks
Reported as:
Median · Weeks
Time to Onset of 24-week Confirmed Disability Progression
WeeksOcrelizumab
Time to Onset of 24-week Confirmed Disability ProgressionNA (NA to NA)
SecondaryTime to Onset of First Protocol-Defined Relapse

A protocol-defined multiple sclerosis (MS) relapse is an occurrence of new or worsening neurological symptoms attributable to MS that meets the following criteria: * Symptoms must persist for \>24 hours and should not be attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications) * Symptoms should be preceded by neurological stability for at least 30 days * Symptoms should be accompanied by new objective neurological worsening determined with a timely EDSS/ Functional Systems Score (FSS) assessment, consistent with an increase of at least: * ≥ 0.5 points on EDSS scale * or ≥ 2 points on one of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual * or ≥ 1 point on two or more of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual

Time frame:
Baseline up to 96 Weeks
Reported as:
Median · Weeks
Time to Onset of First Protocol-Defined Relapse
WeeksOcrelizumab
Time to Onset of First Protocol-Defined RelapseNA (NA to NA)
SecondaryTime to Onset of First New and/or Enlarging T2 Lesion
Time frame:
Baseline up to 96 Weeks
Reported as:
Median · Weeks
Time to Onset of First New and/or Enlarging T2 Lesion
WeeksOcrelizumab
Time to Onset of First New and/or Enlarging T2 LesionNA (NA to NA)
SecondaryMean Number of T1 Gd-enhancing Lesions Per MRI Scan at Weeks 24, 48 and 96

Mean number of T1 Gd-enhancing lesions per MRI scan: Total number of T1 Gd-enhanced lesions divided by the total number of interpretable MRI scans

Time frame:
Weeks: 24, 48, 96
Reported as:
Mean · Lesions per scan
Mean Number of T1 Gd-enhancing Lesions Per MRI Scan at Weeks 24, 48 and 96
Lesions per scanOcrelizumab
Week 240.004 (0.001 to 0.014)
Week 480.004 (0.001 to 0.011)
Week 96NA (NA to NA)
SecondaryChange From Baseline to Week 96 in Total T2 Lesion Volume Detected by Brain MRI From
Time frame:
Baseline, Week 96
Reported as:
Mean · mL
Change From Baseline to Week 96 in Total T2 Lesion Volume Detected by Brain MRI From
mLOcrelizumab
Change From Baseline to Week 96 in Total T2 Lesion Volume Detected by Brain MRI From-558.6 ± 1194.6
SecondaryPercentage Change From Baseline to Week 96 in Total T2 Lesion Volume Detected by Brain MRI
Time frame:
Baseline, Week 96
Reported as:
Mean · Percentage Change From Baseline
Percentage Change From Baseline to Week 96 in Total T2 Lesion Volume Detected by Brain MRI
Percentage Change From BaselineOcrelizumab
Percentage Change From Baseline to Week 96 in Total T2 Lesion Volume Detected by Brain MRI-8.5 ± 18.2
SecondaryVolume of New and/or Enlarging T2 Hyperintense Lesions Volume of Lesions Per MRI Scan at Weeks 24, 48, 96

The number of new and/or enlarging T2 lesions at week 24, 48 and 96 is calculated as the sum of the individual number of new and/or enlarging lesions at each visit. Data from other unscheduled assessments is included in this summary or analysis.

Time frame:
Weeks 24, 48, 96
Reported as:
Mean · uL
Volume of New and/or Enlarging T2 Hyperintense Lesions Volume of Lesions Per MRI Scan at Weeks 24, 48, 96
uLOcrelizumab
Week 2421.4 ± 241.7
Week 4823.1 ± 510.2
Week 963.7 ± 41.6
SecondaryMean Number of New and/or Enlarging T2 Hyperintense Lesions Per MRI Scan

Mean number of new and/or enlarging T2 hyperintense lesions per MRI scan: Total number of new and/or enlarging T2 hyperintense lesions divided by the total number of interpretable MRI scans

Time frame:
Weeks 24, 48, 96
Reported as:
Mean · Lesions per scan
Mean Number of New and/or Enlarging T2 Hyperintense Lesions Per MRI Scan
Lesions per scanOcrelizumab
Week 240.053 (0.038 to 0.075)
Week 480.009 (0.004 to 0.017)
Week 960.011 (0.006 to 0.020)
SecondaryChange From Baseline at Week 48 and 96 in T1 Hypointense Lesion Volume
Time frame:
Weeks 48, 96
Reported as:
Mean · mL
Change From Baseline at Week 48 and 96 in T1 Hypointense Lesion Volume
mLOcrelizumab
Week 48-416.5 ± 1224.3
Week 96-528.5 ± 1144.7
SecondaryPercentage Change From Baseline at Week 48 and 96 in T1 Hypointense Lesion Volume
Time frame:
Weeks 48, 96
Reported as:
Mean · Percentage change from baseline
Percentage Change From Baseline at Week 48 and 96 in T1 Hypointense Lesion Volume
Percentage change from baselineOcrelizumab
Week 48-4.0 ± 149.7
Week 96-12.5 ± 21.1
SecondaryAdjusted Mean Change From Baseline at Week 48 and 96 in T1 Hypointense Lesion Volume
Time frame:
Weeks 48, 96
Reported as:
Mean · mL
Adjusted Mean Change From Baseline at Week 48 and 96 in T1 Hypointense Lesion Volume
mLOcrelizumab
Week 48-461.8 (-613.8 to -309.7)
Week 96-576.5 (-727.0 to -426.1)
SecondaryAdjusted Mean Percentage Change From Baseline in Brain Volume
Time frame:
Weeks 24, 48, 96
Reported as:
Mean · Mean percentage change from baseline
Adjusted Mean Percentage Change From Baseline in Brain Volume
Mean percentage change from baselineOcrelizumab
Week 24-0.153 (-0.259 to -0.047)
Week 48-0.445 (-0.556 to -0.334)
Week 96-0.805 (-0.940 to -0.669)
SecondaryAdjusted Mean Percentage Change From Baseline in Cortical Grey Matter Volume
Time frame:
Weeks 48, 96
Reported as:
Mean · Mean percentage change from baseline
Adjusted Mean Percentage Change From Baseline in Cortical Grey Matter Volume
Mean percentage change from baselineOcrelizumab
Week 48-0.312 (-0.606 to -0.019)
Week 96-0.618 (-0.928 to -0.308)
SecondaryAdjusted Mean Percentage Change From Baseline in White Matter Volume
Time frame:
Weeks 48, 96
Reported as:
Mean · Mean percentage change from baseline
Adjusted Mean Percentage Change From Baseline in White Matter Volume
Mean percentage change from baselineOcrelizumab
Week 48-0.382 (-0.609 to -0.154)
Week 96-0.745 (-0.983 to -0.507)
SecondaryMean Change From Baseline in Cognitive Performance (Processing Speed/Working Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Symbol Digit Modalities Test (SDMT) Score

Brief International Cognitive Assessment for MS (BICAMS) is assessing cognitive processing speed and verbal and visual memory. Symbol Digits Modalities Test (SDMT) is assessing processing speed/working memory. The SDMT presents a series of nine symbols, each paired with a single digit in a key at the top of a standard sheet of paper. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 sec. There is a single outcome measure - the number correct over the 90 sec time span. The higher the results, the better processing speed/working memory.

Time frame:
Baseline, Weeks: 48, 96
Reported as:
Mean · Correct responses over 90 seconds
Mean Change From Baseline in Cognitive Performance (Processing Speed/Working Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Symbol Digit Modalities Test (SDMT) Score
Correct responses over 90 secondsOcrelizumab
Baseline53.8 ± 13.0
Week 482.5 ± 9.8
Week 961.3 ± 10.2
SecondaryChange From Baseline in Cognitive Performance (Visuospatial Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Brief Visuospatial Memory Test-Revised (BVMT-R) Score

Brief International Cognitive Assessment for MS (BICAMS) is assessing cognitive processing speed and verbal and visual memory. Brief Visuospatial Memory Test-Revised (BVMT-R) is assessing visuospatial memory. In this test, six abstract designs are presented for 10 sec. The display is removed from view and patients render the stimuli via pencil on paper manual responses. Each design receives from 0 to 2 points representing accuracy and location. There are three learning trials, and the outcome measure is the total number of points earned over the three learning trials, thus the scale range is 0-36. The higher the result, the better visual/spatial memory.

Time frame:
Baseline, Weeks 48, 96
Reported as:
Mean · Points on scale
Change From Baseline in Cognitive Performance (Visuospatial Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Brief Visuospatial Memory Test-Revised (BVMT-R) Score
Points on scaleOcrelizumab
Baseline25.0 ± 6.3
Week 48-1.9 ± 5.3
Week 96-1.5 ± 5.4
SecondaryPercentage Change From Baseline in Cognitive Performance (Processing Speed/Working Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Symbol Digit Modalities Test (SDMT) Score

Brief International Cognitive Assessment for MS (BICAMS) is assessing cognitive processing speed and verbal and visual memory. Symbol Digits Modalities Test (SDMT) is assessing processing speed/working memory. The SDMT presents a series of nine symbols, each paired with a single digit in a key at the top of a standard sheet of paper. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 sec. There is a single outcome measure - the number correct over the 90 sec time span.

Time frame:
Baseline, Weeks 48, 96
Reported as:
Mean · Percentage change from baseline
Percentage Change From Baseline in Cognitive Performance (Processing Speed/Working Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Symbol Digit Modalities Test (SDMT) Score
Percentage change from baselineOcrelizumab
Week 487.2 ± 30.8
Week 964.8 ± 30.6
SecondaryPercentage Change From Baseline in Cognitive Performance (Visuospatial Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Brief Visuospatial Memory Test-Revised (BVMT-R) Score

Brief International Cognitive Assessment for MS (BICAMS) is assessing cognitive processing speed and verbal and visual memory. Brief Visuospatial Memory Test-Revised (BVMT-R) is assessing visuospatial memory. In this test, six abstract designs are presented for 10 sec. The display is removed from view and patients render the stimuli via pencil on paper manual responses. Each design receives from 0 to 2 points representing accuracy and location. There are three learning trials, and the outcome measure is the total number of points earned over the three learning trials, thus the scale range is 0-36. The higher the result, the better visual/spatial memory.

Time frame:
Baseline, Weeks: 48, 96
Reported as:
Mean · Percentage change from baseline
Percentage Change From Baseline in Cognitive Performance (Visuospatial Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Brief Visuospatial Memory Test-Revised (BVMT-R) Score
Percentage change from baselineOcrelizumab
Week 48-4.4 ± 31.1
Week 96-2.0 ± 33.7
SecondaryPercentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
Baseline up to to 96 weeks after the end of the Treatment Period
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Percentage of ParticipantsOcrelizumabOcrelizumab Safety Follow-up
Any AE89.157.8
SAE7.29.4
Deaths0.10
AEs leading to study drug discontinuation1.0NA
SAEs leading to study drug discontinuation0.7NA
AEs leading to dose modification/interruptionb15.0NA
Infusion-related reactions (IRRs)43.20
Serious IRRs0.10
Infections66.928.1
Serious infections1.60
Malignancies0.40
Pregnancies0.71.5

Adverse events

Collected over From Baseline up to to 96 weeks after the end of the Treatment Period. Time frame includes the safety-follow-up period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ocrelizumab1/680 (0.1%)49/680 (7.2%)531/680 (78.1%)
Ocrelizumab Safety Follow-up0/64 (0%)6/64 (9.4%)14/64 (21.9%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventOcrelizumabOcrelizumab Safety Follow-up
OEDEMAGastrointestinal disorders0/6801/64
HEPATITISHepatobiliary disorders1/6801/64
FACIAL BONES FRACTUREInjury, poisoning and procedural complications0/6801/64
INTERVERTEBRAL DISC PROTRUSIONMusculoskeletal and connective tissue disorders1/6801/64
ABORTION SPONTANEOUSPregnancy, puerperium and perinatal conditions1/6801/64
DEPRESSION SUICIDALPsychiatric disorders0/6801/64
ENTERITISGastrointestinal disorders0/6801/64
SINUSITISInfections and infestations3/6800/64
MULTIPLE SCLEROSIS RELAPSENervous system disorders3/6800/64
PNEUMONIAInfections and infestations2/6800/64
Most frequent other events
Showing 10 of 19
Most frequent other events
EventOcrelizumabOcrelizumab Safety Follow-up
INFUSION RELATED REACTIONInjury, poisoning and procedural complications294/6800/64
NASOPHARYNGITISInfections and infestations210/68011/64
HEADACHENervous system disorders154/6800/64
INFLUENZAInfections and infestations92/6800/64
URINARY TRACT INFECTIONInfections and infestations70/6800/64
FATIGUEGeneral disorders67/6800/64
BACK PAINMusculoskeletal and connective tissue disorders57/6800/64
ORAL HERPESInfections and infestations55/6800/64
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations51/6800/64
COUGHRespiratory, thoracic and mediastinal disorders47/6804/64

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Ocrelizumab
Mean34.2 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)Ocrelizumab
Female436
Male244
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ocrelizumab
Hispanic or Latino27
Not Hispanic or Latino579
Unknown or Not Reported74
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ocrelizumab
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American1
White625
More than one race2
Unknown or Not Reported49
08

Study locations

163 sites
  • St George Hospital
    Kogarah, New South Wales, New South Wales 2217, Australia
  • Hospital Erasme
    Bruxelles, 1070, Belgium
  • Cliniques Universitaires St-Luc
    Bruxelles, 1200, Belgium
  • UZ Antwerpen
    Edegem, 2650, Belgium
  • UZ Gent
    Gent, 9000, Belgium
  • CHU Tivoli
    La Louvière, 7100, Belgium
  • UZ Leuven Gasthuisberg
    Leuven, 3000, Belgium
  • Nationaal MS Centrum
    Melsbroek, 1820, Belgium
  • Revalidatie en MS Centrum
    Overpelt, 3900, Belgium
  • Fakultni nemocnice u sv. Anny; Neurologicka klinika
    Brno, 656 91, Czechia
  • Nemocnice Jihlava; NEU-Neurologicke oddeleni
    Jihlava, 58633, Czechia
  • VFN Praha Poliklinika Rs Centrum - Budova A
    Prague, 12808, Czechia
  • Fakultni nemocnice Motol; Neurologicka klinika
    Praha, 150 06, Czechia
  • Aarhus Universitetshospital, Neurologisk Afd. F, Skleroseklinikken
    Aarhus N, 8200, Denmark
  • Rigshospitalet Glostrup; Neurologisk Klinik
    Glostrup, 2600, Denmark
  • Odense Universitetshospital, Neurologisk Afdeling N
    Odense C, 5000, Denmark
  • Sydjysk Skleroseklinik - Sønderborg
    Sønderborg, 6400, Denmark
  • East Tallinn Central Hospital; Neurology Department
    Tallinn, 10138, Estonia
  • West Tallinn Central Hospital
    Tallinn, 10617, Estonia
  • Tartu University Hospital
    Tartu, 51014, Estonia
  • Terveystalo Tampere
    Tampere, 33100, Finland
  • Mehiläinen Neo Turku
    Turku, 20520, Finland
  • CHU de Besancon Hopital Jean Minjoz; Service de Neurologie
    Besançon, 25030, France
  • Groupe Hospitalier Pellegrin; Service de neurochirurgie B
    Bordeaux, 33076, France
  • Hopital Neurologique et Neurochirurgical Pierre Wertheimer; Service de Neurologie A
    Bron, 69677, France
  • Hopital Gabriel Montpied CHU de Clermont-Ferrand; Service de Neurologie B
    Clermont-Ferrand, 63003, France
  • Hopital Roger Salengro; Service de Neurologie
    Lille, France
  • CHU de la Timone - Hopital d Adultes; Service de Neurologie
    Marseille, 13005, France
  • Hopital Gui de Chauliac; Neurologie
    Montpellier, 34295, France
  • Hôpital Guillaume et René Laënnec; Service Neurologie
    Nantes, 44805, France
  • Hôpital Pasteur; Service de Neurologie
    Nice, 06002, France
  • Fondation Rothschild; Service de Neurologie
    Paris, 75019, France
  • Groupe Hospitalier Pitié- Salpétrière; Service Neurologie
    Paris, 75651, France
  • Hôpital Maison Blanche; Service de Neurologie
    Reims, 51092, France
  • Hôpitaux Universitaires de strasbourg - hôpital civil
    Strasbourg, 67091, France
  • CHU toulouse - Hôpital Purpan; Departement de Neurologie
    Toulouse, 31059, France
  • CHRU - Hôpital Bretonneau; Neurologie
    Tours, 37000, France
  • Klinikum Augsburg, Neurologische Klinik und klinische Neurophysiologie
    Augsburg, 86156, Germany
  • Marianne-Strauß-Klinik; Behandlung Kempfen für Multip Sklero Kranke gemeinnütz GmbH
    Berg, 82335, Germany
  • Charite - Universitatsmedizin Berlin; Klinik fur Neurologie
    Berlin, 10117, Germany
  • Praxis Dr. Said Masri
    Berlin, 12099, Germany
  • Gemeinschaftspraxis Dr.med. Reinhard Ehret/Dr. med Wolfram von Pannwitz
    Berlin, 12163, Germany
  • Jüdisches Krankenhaus Berlin; Abteilung fur Neurologie
    Berlin, 13347, Germany
  • St. Josef-Hospital, Klinik für Neurologie
    Bochum, 44791, Germany
  • Gesundheitszentrum St. Johannes Hospital; Neurolog. Gemeinschaftspraxis Dres. Schmidt, Neudecker etc
    Bonn, 53111, Germany
  • PNP Buchholz, Praxis für Neurologie - Psychiatrie, Dres. Dee/Gößling/Hoge
    Buchholz, 21244, Germany
  • Studienzentrum für Neurologie und Psychiatrie
    Böblingen, 71034, Germany
  • Universitätsklinikum "Carl Gustav Carus", Zentrum für Klinische Neurowissenschaften
    Dresden, 01307, Germany
  • Gemeinschaftspraxis für Neurologie; Dr. Katrin Schulte, Dr. Nils Richter, Dr. Margarete Capito
    Düsseldorf, 40211, Germany
  • NeuroCentrum Odenwald; Dres. Reifschneider, Unsorg, Ries, Schumann, Hoffmann, Knoblich
    Erbach/Odenwald, 64711, Germany
  • Universitaetsklinikum Frankfurt; Klinik für Neurologie
    Frankfurt, 60528, Germany
  • Universitätsklinikum Freiburg, Klinik für Neurologie und Neurophysiologie
    Freiburg, 79106, Germany
  • Universiätsklinikum Hamburg-Eppendorf , Multiple Sklerose Tagesklinik u. Ambulanz Neurol. Poliklinik
    Hamburg, 20246, Germany
  • Neurologische Praxisgemeinschaft Hamburger-Straße; Dres. Müller-Habich/Emrich/Vogt
    Hamburg, 22083, Germany
  • MultipEL Studies - Institut für klinische Studien
    Hamburg, 22179, Germany
  • Henriettenstiftung Hannover; Klinik fuer Neurologie und Klinische Neurophysiologie
    Hannover, 30171, Germany
  • Neurologische Klinik, Universitätsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Oberhavel Kliniken GmbH, Klinik Hennigsdorf, Neurologie
    Hennigsdorf, 16761, Germany
  • Neurozentrum am Klosterforst in Itzehoe
    Itzehoe, 25524, Germany
  • Neurologische Gemeinschaftspraxis Kassel und Vellmar, Ch. Lassek, Dres. Ammerbach, Fetzer, M. Fische
    Kassel, 34121, Germany
  • PANAKEIA - Arzneimittelforschung Leipzig GmbH
    Leipzig, 04275, Germany
  • Universitätsklinikum Magdeburg,Otto-von-Guericke-Universität A.ö.R., Klinik für Neurologie
    Magdeburg, 39120, Germany
  • Universitaetsklinikum Mainz - PS; Klinik und Poliklinik fuer Neurologie
    Mainz, 55131, Germany
  • Universitaetsklinikum Marburg; Klinik fuer Neurologie
    Marburg, 35043, Germany
  • Max-Planck-Institut für Psychiatrie
    München, 80804, Germany
  • Klinikum Grosshadern der LMU; Neuroimmunologie II
    München, 81377, Germany
  • Klinikum rechts der Isar der TU Muenchen; Neurologische Klinik und Poliklinik im Neuro-Kopf-Zentrum
    München, 81675, Germany
  • Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie
    Münster, 48149, Germany
  • Ruppiner Kliniken, Hochschulklinikum der Medizinischen Hochschule Brandenburg, Klinik für Neurologie
    Neuruppin, 16816, Germany
  • AMEOS Klinikum Oldenburg, Klinik für Neurologie und Neurophysiologie
    Oldenburg in Holstein, 23758, Germany
  • St. Josefs-Krankenhaus, Klinik für Neurologie
    Potsdam, 14471, Germany
  • NeuroConcept AG C/O mind mvz GmbH
    Stuttgart, 70182, Germany
  • Universitätsklinikum Tübingen, Zentrum für Neurologie
    Tübingen, 72076, Germany
  • NeuroPoint, Gesellschaft für vorbeugende Gesundheitspflege mbH
    Ulm, 89073, Germany
  • Studienzentrum Nordwest, Dr. med. Joachim Springub / Herr Wolfgang Schwarz
    Westerstede, 26655, Germany
  • Cork University Hospital; Clinical Research Facility
    Cork, Ireland
  • St Vincents University Hospital
    Dublin 4, Ireland
  • Beaumont Hospital
    Dublin, 9, Ireland
  • Ospedale SS. Annunziata - Clinica Neurologica - Centro Sclerosi Multipla
    Chieti, Abruzzo 66013, Italy
  • Ospedale San Salvatore; Clinica Neurologica - Centro Sclerosi Multipla
    L'Aquila, Abruzzo 67100, Italy
  • A. O. U. Federico II; Dip Neuroscienze, Scienze Riproduttive ed Odontostomatologiche
    Napoli, Campania 80131, Italy
  • Università degli Studi della Campania Luigi Vanvitelli; Dip. Ass. Integrato Med Int-II Clinica Neur
    Napoli, Campania 80131, Italy
  • Ospedale Bellaria; Istituto delle Scienze Neurologiche - UO RIABILITAZIONE SCLEROSI MULTIPLA
    Bologna, Emilia-Romagna 40139, Italy
  • Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla
    Roma, Lazio 00133, Italy
  • Ospedale S.Camillo Forlanini; UOSD Day Hospital Neurologico e Neurochirurgico
    Roma, Lazio 00152, Italy
  • Policlinico Universitario A. Gemelli; UOC Neurologia - Centro Sclerosi Multipla
    Roma, Lazio 00168, Italy
  • Azienda Ospedaliera Sant'Andrea; UOC Neurologia
    Roma, Lazio 00189, Italy
  • Irccs A.O.U.San Martino Ist; Dinogmi
    Genova, Liguria 16132, Italy
  • ASST PAPA GIOVANNI XXIII Neurologia USS Malattie Autoimmuni Centro Sclerosi Multipla
    Bergamo, Lombardia 24127, Italy
  • Ospedale S.Antonio Abate; Neurologia 2 - Sclerosi Multipla e Recupero Neurologico
    Gallarate, Lombardia 21013, Italy
  • Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico; UOSD Malattie Neurodegenerative
    Milano, Lombardia 20122, Italy
  • IRCCS Ospedale San Raffaele; Neurologia Neurofisiologia Neuroriabilitazione-Centro Sclerosi Multipla
    Milano, Lombardia 20132, Italy
  • Fond. Istituto Neurologico C.Besta; UO Neurologia IV - Neuroimmunologia Malattie Neuromuscolari
    Milano, Lombardia 20133, Italy
  • Ospedale Civile di Montichiari; Centro Sclerosi Multipla
    Montichiari, Lombardia 25018, Italy
  • IRCCS Istituto Neurologico C. Mondino-Dip. Neurologia Neuroriabilitazione S.S. Sclerosi Multipla
    Pavia, Lombardia 27100, Italy
  • AOU Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi; SOD Clinica Neurologica-Am.Sclerosi Multipla
    Ancona, Marche 60100, Italy
  • IRCCS Istituto Neurologico Neuromed; Centro per lo Studio e la Cura della Sclerosi Multipla
    Pozzilli, Molise 86077, Italy
  • Ospedale Dimiccoli Barletta; Dipartimento Testa-Collo - UO Neurologia
    Barletta, Puglia 70051, Italy
  • IRCCS Ospedale Casa Sollievo Della Sofferenza; SC Neurologia
    San Giovanni Rotondo, Puglia 71013, Italy
  • Ospedale Binaghi; Centro Sclerosi Multipla
    Cagliari, Sardegna 09126, Italy

Showing the first 100 of 163 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Vermersch P, Oreja-Guevara C, Siva A, Van Wijmeersch B, Wiendl H, Wuerfel J, Buffels R, Kadner K, Kuenzel T, Comi G; CASTING Investigators. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial. Eur J Neurol. 2022 Mar;29(3):790-801. doi: 10.1111/ene.15171. Epub 2021 Nov 25. PubMed 34748672 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2016 to primary completion in Oct 2019, 37 months.

Results were first posted in Feb 2021, 1 year 3 months after primary completion.

Of 28 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 37 months is close to that.

Counting every sponsor, half of 38 studies reached it within 48 months; a quarter within 27 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2016
First posted
Aug 10, 2016
StartActual
Sep 9, 2016
Primary completionActual
Oct 25, 2019
CompletionActual
Dec 15, 2020
Results first posted
Feb 3, 2021
Last update
Jan 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02861014
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 10, 2016
Start date
Sep 9, 2016
Primary completion
Oct 25, 2019
Completion
Dec 15, 2020
Results posted
Feb 3, 2021
Last update
Jan 27, 2022

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion